Alternative Health Products (Detail Textuals) - USD ($) |
2 Months Ended | 12 Months Ended | ||||
---|---|---|---|---|---|---|
Aug. 11, 2015 |
Oct. 31, 2017 |
Aug. 31, 2018 |
Aug. 31, 2017 |
Aug. 31, 2016 |
Nov. 12, 2014 |
|
Alternative Health Products [Line Items] | ||||||
License costs | $ 25,185 | $ 29,750 | $ 45,615 | |||
Useful life | 20 years | |||||
Poppy's Teas LLC. | ||||||
Alternative Health Products [Line Items] | ||||||
Ownership interest | 100.00% | 51.00% | ||||
Amount of compensation | $ 70,000 | |||||
Royalty percentage | 5.00% | |||||
Term of royalty contract | 20 years | |||||
Poppy's Teas LLC. | License | ||||||
Alternative Health Products [Line Items] | ||||||
License costs | $ 10,000 | |||||
License agreement, term of contract | 35 years |
X | ||||||||||
- Definition Line items represent alternative health products. No definition available.
|
X | ||||||||||
- Definition License agreement, term of contract No definition available.
|
X | ||||||||||
- Definition Royalty percentage No definition available.
|
X | ||||||||||
- Definition Term of Royalty contract No definition available.
|
X | ||||||||||
- Definition The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. No definition available.
|
X | ||||||||||
- Definition The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|